MX369738B - Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas. - Google Patents

Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas.

Info

Publication number
MX369738B
MX369738B MX2016007273A MX2016007273A MX369738B MX 369738 B MX369738 B MX 369738B MX 2016007273 A MX2016007273 A MX 2016007273A MX 2016007273 A MX2016007273 A MX 2016007273A MX 369738 B MX369738 B MX 369738B
Authority
MX
Mexico
Prior art keywords
crystalline
fuel cell
phthalazinamine
pyridinyl
pyrimidinyl
Prior art date
Application number
MX2016007273A
Other languages
English (en)
Other versions
MX2016007273A (es
Inventor
Bio Matthew
Chaves Mary
Peterson Matthew
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2016007273A publication Critical patent/MX2016007273A/es
Publication of MX369738B publication Critical patent/MX369738B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con formas cristalinas y formas co-cristalinas de sales farmacéuticamente aceptables del compuesto, N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil) -4-(4-metil-2-tienil)-1-ftalazinamina (AMG 900), y las composiciones farmacéuticas que comprenden las formas cristalinas y co-cristalinas del mismo. La invención proporciona además los usos de las formas cristalinas y composiciones, para tratar cáncer, incluyendo diversos tipos de tumores sólidos y cáncer hematológico incluyendo mieloma y leucemia.
MX2016007273A 2013-12-03 2014-11-25 Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas. MX369738B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911341P 2013-12-03 2013-12-03
PCT/US2014/067385 WO2015084649A1 (en) 2013-12-03 2014-11-25 Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof

Publications (2)

Publication Number Publication Date
MX2016007273A MX2016007273A (es) 2016-12-14
MX369738B true MX369738B (es) 2019-11-20

Family

ID=52021465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007273A MX369738B (es) 2013-12-03 2014-11-25 Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas.

Country Status (10)

Country Link
US (1) US10053452B2 (es)
EP (1) EP3077392B1 (es)
JP (3) JP6634016B2 (es)
KR (1) KR20160087902A (es)
AU (1) AU2014357545B2 (es)
CA (1) CA2932560C (es)
ES (1) ES2784325T3 (es)
MX (1) MX369738B (es)
SG (1) SG11201604517WA (es)
WO (1) WO2015084649A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3077392B1 (en) * 2013-12-03 2020-01-15 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl - 2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
WO2017156403A1 (en) * 2016-03-11 2017-09-14 Stealth Biotherapeutics Crystalline salt forms
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
KR101300424B1 (ko) 2006-01-23 2013-08-26 암젠 인크 오로라 키나제 조절제 및 사용 방법
ES2528485T3 (es) 2009-09-11 2015-02-10 Amgen, Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos
WO2013149026A2 (en) 2012-03-30 2013-10-03 The Johns Hopkins University Use of n-(4-((3-(2-amino-4-pyrimidinyl) -2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
JP2015518053A (ja) 2012-05-31 2015-06-25 アムジエン・インコーポレーテツド 癌の治療のためのａｍｇ９００の使用
EP3077392B1 (en) * 2013-12-03 2020-01-15 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl - 2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof

Also Published As

Publication number Publication date
ES2784325T3 (es) 2020-09-24
JP6634016B2 (ja) 2020-01-22
CA2932560C (en) 2022-11-15
MX2016007273A (es) 2016-12-14
KR20160087902A (ko) 2016-07-22
EP3077392B1 (en) 2020-01-15
JP2016539145A (ja) 2016-12-15
SG11201604517WA (en) 2016-07-28
AU2014357545B2 (en) 2018-10-25
EP3077392A1 (en) 2016-10-12
JP2019189615A (ja) 2019-10-31
CA2932560A1 (en) 2015-06-11
US20160304504A1 (en) 2016-10-20
US10053452B2 (en) 2018-08-21
JP2022068350A (ja) 2022-05-09
WO2015084649A1 (en) 2015-06-11
AU2014357545A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
GEP201706699B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MA32580B1 (fr) Composes de pyrimidine, compositions et procedes d'utilisation
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
EA201991884A2 (ru) Ингибиторы g12c kras
EA201690752A1 (ru) Ингибиторы g12c kras
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
PH12015502852A1 (en) Bromodomain inhibitor
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
MX2016007273A (es) Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX2015012005A (es) Inhibidores de bromodominio.
UA111770C2 (uk) Інгібітори бромдомену
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX340360B (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
PE20141408A1 (es) Aminoquinazolinas como inhibidores de quinasa
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives

Legal Events

Date Code Title Description
FG Grant or registration